USANA Health Sciences, Inc. (NYSE:USNA) Director Timothy E. Wood sold 426 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.35, for a total value of $34,655.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NYSE USNA opened at $81.18 on Friday. The firm has a market cap of $1.71 billion, a P/E ratio of 16.08 and a beta of 0.90. USANA Health Sciences, Inc. has a 1-year low of $43.01 and a 1-year high of $92.26. The business’s 50 day moving average is $80.14 and its 200-day moving average is $75.27.
USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, July 21st. The company reported $1.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.24. The company had revenue of $258.99 million for the quarter, compared to analyst estimates of $267.80 million. USANA Health Sciences had a return on equity of 32.87% and a net margin of 10.35%. During the same quarter last year, the company earned $0.91 earnings per share. On average, research analysts predict that USANA Health Sciences, Inc. will post 5.16 earnings per share for the current fiscal year.
USNA has been the subject of a number of recent analyst reports. Tigress Financial reaffirmed a “buy” rating on shares of USANA Health Sciences in a research report on Tuesday, May 12th. Zacks Investment Research raised USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $94.00 price objective for the company in a research report on Thursday, June 18th. Finally, ValuEngine cut USANA Health Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $79.50.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
See Also: What is an overbought condition?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.